GlassScriptPhysician profile
Brett Robert Barlow
NPI 1700240264
$9,544.84
in general payments reported to CMS, 2019-2025
65 companies · $2,708 in 2025
The $2,708 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $75.00 · 2022: $878 · 2023: $2,491 · 2024: $3,146 · 2025: $2,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,197 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120 · Education: $26.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,197.30 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
| Education | $26.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $758.57 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $640.99 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $619.17 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $571.38 | 2022-2025 | Imfinzi, Enhertu, Calquence |
| Janssen Biotech, INC. | $425.74 | 2023-2025 | Rybrevant, Tecvayli, Talvey |
| E.R. Squibb & Sons, L.L.C. | $371.69 | 2022-2025 | Opdivo, Opdualag |
| Seagen INC. | $318.07 | 2022-2023 | Padcev, Adcetris, Tukysa |
| Celgene Corporation | $303.82 | 2022-2025 | Reblozyl, Opdivo, Opdualag |
| Astellas Pharma US INC | $302.10 | 2019-2025 | Xtandi, Vyloy |
| Incyte Corporation | $263.22 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Genzyme Corporation | $250.68 | 2022-2025 | |
| Daiichi Sankyo INC. | $222.93 | 2023-2025 | Enhertu, Vanflyta |
| Abbvie INC. | $212.56 | 2023-2025 | Venclexta |
| Lilly USA, LLC | $200.15 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $198.61 | 2022-2025 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $195.91 | 2022-2024 | Tecentriq, Tecentriq Hybreza, Columvi |
| Beigene USA, INC. | $193.88 | 2022-2025 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $184.45 | 2022-2025 | Ninlaro, Fruzaqla, Iclusig |
| Stemline Therapeutics INC. | $180.11 | 2023-2025 | Orserdu, Elzonris |
| Beone Medicines USA, INC. | $170.31 | 2025 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $160.64 | 2022-2023 | Imbruvica, Epkinly |
| Amgen INC. | $149.45 | 2020-2023 | Blincyto, Kyprolis, Vectibix |
| Regeneron Healthcare Solutions, INC. | $148.79 | 2023-2025 | Libtayo |
| Blueprint Medicines Corporation | $148.48 | 2022-2025 | Ayvakit |
| Tersera Therapeutics LLC | $145.09 | 2022-2025 | Xermelo, Zoladex, Quzyttir |
| Gilead Sciences, INC. | $142.91 | 2022-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $140.60 | 2022-2025 | Ultomiris, Soliris |
| Glaxosmithkline, LLC. | $138.28 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Sumitomo Pharma America, INC. | $124.32 | 2023-2025 | Orgovyx |
| Sobi, INC | $118.43 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.52 | 2022-2025 | Gilotrif |
| Jazz Pharmaceuticals INC. | $98.56 | 2022-2025 | Zepzelca |
| Springworks Therapeutics, INC. | $97.58 | 2024-2025 | Ogsiveo |
| Kite Pharma, INC. | $81.08 | 2022-2025 | Yescarta |
| Servier Pharmaceuticals LLC | $78.88 | 2024-2025 | |
| Array Biopharma INC | $78.42 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Shield Therapeutics INC | $74.13 | 2024-2025 | |
| Emd Serono, INC. | $70.61 | 2023-2025 | Bavencio |
| Ipsen Biopharmaceuticals, INC | $68.40 | 2022-2024 | Somatuline Depot, Onivyde |
| Dendreon Pharmaceuticals LLC | $62.76 | 2025 | Provenge |
| Adaptive Biotechnologies Corporation | $61.83 | 2024-2025 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $54.32 | 2023-2025 | |
| Deciphera Pharmaceuticals INC. | $51.29 | 2023-2025 | Qinlock |
| Exelixis INC. | $49.98 | 2022-2023 | Cabometyx |
| Mirati Therapeutics, INC. | $47.06 | 2023-2024 | Krazati |
| Adc Therapeutics America, INC. | $46.81 | 2022-2023 | |
| Pharmacosmos Therapeutics INC. | $45.00 | 2023 | Monoferric |
| Karyopharm Therapeutics INC. | $36.60 | 2025 | Xpovio |
| Pharmaessentia USA Corporation | $33.75 | 2024 | Besremi |
| Rigel Pharmaceuticals, INC. | $28.14 | 2022-2023 | Tavalisse, Rezlidhia |
| Spectrum Pharmaceuticals INC. | $27.61 | 2025 | Rolvedon |
| Immunogen, INC. | $21.33 | 2024 | Elahere |
| Acrotech Biopharma INC. | $21.13 | 2023 | Beleodaq |
| Agios Pharmaceuticals, INC. | $20.65 | 2024 | Pyrukynd |
| Tolmar, INC. | $20.24 | 2025 | Eligard |
| Taiho Oncology, INC. | $18.63 | 2024 | |
| Janssen Scientific Affairs, LLC | $18.62 | 2025 | Rybrevant |
| G1 Therapeutics, INC. | $17.97 | 2023 | Cosela |
| Aveo Pharmaceuticals, INC. | $17.16 | 2023 | Fotivda |
| Genmab U.S., INC. | $17.09 | 2024 | Epkinly |
| Recordati_rare_diseases_inc. | $16.24 | 2025 | Sylvant |
| Kyowa Kirin, INC. | $15.38 | 2024 | Poteligeo |
| Fennec Pharmaceuticals, INC. | $15.34 | 2025 | Fyarro |
| Puma Biotechnology, INC. | $14.27 | 2025 | |
| Iovance Biotherapeutics, INC. | $12.13 | 2024 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Barlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.